Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA).

Full DD Report for VNDA

You must become a subscriber to view this report.


Recent News from (NASDAQ: VNDA)

Vanda Pharmaceuticals Announces Participation at September 2018 Investor Conferences
WASHINGTON , Sept. 4, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2018 : The Citigroup 13 th Annual Biotech Conference in Boston on Wednesday, Septem...
Source: PR Newswire
Date: September, 04 2018 16:35
By The Numbers: Growth Leaders With Strong Momentum
Investing in high-growth stocks can generate outstanding returns when done right. In essence, a stock is simply a share in the ownership of a business, and businesses with superior growth rates tend to generate higher returns for investors over the long term. However, implementing a solid gr...
Source: SeekingAlpha
Date: August, 28 2018 10:24
Vanda Wins Denial of Petition For Rehearing on Fanapt®
WASHINGTON , Aug. 14, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit denied petitions for panel rehearing and rehearing en banc filed by West-Ward Pharmaceuticals, a subsidiary of Hikma Pharmace...
Source: PR Newswire
Date: August, 14 2018 16:45
Vanda Pharmaceuticals Announces the Appointment of General Counsel
WASHINGTON , Aug. 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has named Timothy Williams as Vanda's Senior Vice President, General Counsel and Secretary. "I am very pleased to welcome Tim to the Vanda executive management team," s...
Source: PR Newswire
Date: August, 13 2018 16:01
Vanda Pharmaceuticals Inc. (VNDA) CEO Mihael Polymeropoulos on Q2 2018 Results - Earnings Call Transcript
Vanda Pharmaceuticals Inc. (VNDA) Q2 2018 Earnings Conference Call August 1, 2018, 04:30 PM ET Executives James Kelly - EVP and CFO Mihael Polymeropoulos - President and CEO Analysts Jason Butler - JMP Securities Joel Beatty - Citi Matthew Andrews - Jefferies Corey Davi...
Source: SeekingAlpha
Date: August, 01 2018 21:22
Vanda Pharmaceuticals beats by $0.32, beats on revenue
Vanda Pharmaceuticals (NASDAQ: VNDA ): Q2 EPS of $0.14 beats by $0.32 . More news on: Vanda Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 01 2018 16:04
Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results
WASHINGTON , Aug. 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA ) today announced financial and operational results for the second quarter ended June 30, 2018 . "We are excited with the year to date HETLIOZ sales performance, which demonstrates continued str...
Source: PR Newswire
Date: August, 01 2018 16:01
Playing The Expectations Game In Biotech
Investing in biotech stocks is not for the faint of heart. When positioned in the right biotech stocks, investors can be rewarded with explosive revenue growth and booming profitability from such companies, which generally means that the stock is delivering massive gains. On the other hand, th...
Source: SeekingAlpha
Date: July, 17 2018 21:11
Vanda Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 1, 2018
WASHINGTON , July 17, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2018 on Wednesday, August 1, 2018 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesda...
Source: PR Newswire
Date: July, 17 2018 16:30
Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks
Stock Research Monitor: TGTX, RARE, and VNDA LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on TRVN sign up now at www.wallstequities.com/registration . On Monday, July 09, 2018, US markets saw broad based gains with eight out of nine sectors finishing the tr...
Source: ACCESSWIRE IA
Date: July, 10 2018 07:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0818.7518.4519.1018.30324,310
2018-05-1717.0016.9017.1516.825362,975
2017-03-1015.0014.9515.0514.8565,517
2017-03-0915.0014.9015.22514.50542,516
2017-03-0814.2514.9515.0514.14879,262

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1857,110123,04046.4158Short
2018-12-1719,19488,70821.6373Cover
2018-12-1433,61980,50541.7601Short
2018-12-1310,49553,98319.4413Cover
2018-12-1232,53191,57035.5258Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VNDA.


About Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Logo for Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $867,643,172 - 05/11/2018
  • Issue and Outstanding: 52,110,701 - 04/19/2018

 


Recent Filings from (NASDAQ: VNDA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 16 2018

 

 


Daily Technical Chart for (NASDAQ: VNDA)

Daily Technical Chart for (NASDAQ: VNDA)


Stay tuned for daily updates and more on (NASDAQ: VNDA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VNDA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VNDA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VNDA and does not buy, sell, or trade any shares of VNDA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/